Randomized Double-Blind, Placebo- Controlled Phase 2 Trial of NuGel, an Inflammasome Inhibitor, for Atopic Dermatitis

Time: 12:00 pm
day: Day 2 - Track B - Morning

Details:

  • A novel inflammasome inhibitor targeting GPCR19
  • GPCR19-P2X7R complex regulating NLRP3 inflammasome
  • Efficient regulation of clinical symptoms assessed by EASI score

Speakers: